MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, October 31, 2013

New TECFIDERA Data Show Sustained Efficacy and Long-Term Safety in MS Patients

New TECFIDERA® (Dimethyl Fumarate) Data Show Sustained Efficacy and Long-Term Safety in a Broad Range of Multiple Sclerosis Patients
  • Interim Results from ENDORSE Extension Study Reinforce Favorable Safety Profile in Patients Treated for Up to Six and a Half Years
  • Analysis of Treatment-Naïve MS Patients Shows Positive Treatment Effects on Relapses, Disability Progression and MRI Outcomes
WESTON, Mass.--(BUSINESS WIRE)--Oct. 4, 2013-- Data presented today show that TECFIDERA® (dimethyl fumarate) continues to offer consistent and strong efficacy combined with a favorable safety profile in a broad range of patients with relapsing-remitting multiple sclerosis (RRMS), including those patients who are newly diagnosed with the disease. These data were presented by Biogen Idec (NASDAQ: BIIB) at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark from 2-5 October.
Interim analyses from the ENDORSE long-term extension study show that TECFIDERA maintained its effect in reducing disease activity in patients treated for four years. No new or worsening safety signals were observed in patients who had received TECFIDERA for up to six and a half years. In addition, a separate post-hoc analysis of the Phase 3 DEFINE and CONFIRM clinical trials shows that TECFIDERA significantly reduced multiple sclerosis (MS) relapses in treatment-naïve patients, while delaying the overall progression of the disease over time.
Because MS is a chronic, life-long disease, physicians and patients need to know they are taking a treatment that will offer them sustained efficacy over the long-term with a consistent safety profile,said Doug Williams, executive vice president, Research and Development, Biogen Idec. These analyses provide important information on the benefits of TECFIDERA’s strong efficacy and favorable safety for a wide range of patients with RRMS – from those treating their MS for the first time to those who have been on TECFIDERA treatment for up to six and a half years.
ENDORSE Interim Clinical Efficacy and MRI Outcomes

ENDORSE is a global, dose-blind extension study to determine the long-term safety and efficacy of TECFIDERA (240 mg, dosed twice a day (BID) or three times a day (TID)). Patients who received two years of TECFIDERA in DEFINE and CONFIRM continued on the same dose in ENDORSE. Patients who previously received placebo or glatiramer acetate (GA; 20 mg subcutaneous daily injection; CONFIRM only) in DEFINE or CONFIRM were randomized 1:1 to TECFIDERA BID or TID. All currently enrolled patients included in the interim analyses had completed four years in the TECFIDERA clinical program (two years in DEFINE or CONFIRM plus two years in ENDORSE). At present, some patients have received TECFIDERA treatment for up to six and a half years.
Interim efficacy results found that patients who continued on TECFIDERA treatment in ENDORSE for two years experienced sustained clinical efficacy (as measured by relapse and disability progression endpoints), similar to what was observed after two years in DEFINE and CONFIRM. These patients also experienced a similarly low frequency of MRI lesions over four years (as measured by new or enlarging T2-hyperintense lesions; new non-enhancing T1-hypointense lesions; and gadolinium-enhanced (Gd+) lesions).
Patients initially randomized to placebo or GA in DEFINE or CONFIRM who then received TECFIDERA in ENDORSE showed clinical and MRI outcomes similar to those observed with TECFIDERA treatment in the pivotal studies.

Continue Reading

To comment - click the comment link shown below
USE OUR SHARE LINKS at the top of this page  - to provide this article to others
REMAIN up to date with MS News and Education
Visit:  to register

No comments: